This anti-CD20 antibody product is approved for use in Canada, under a Notice of Compliance with conditions, for the treatment of patients with CLL who are refractory to fludarabine and alemtuzumab. The product monograph for ARZERRA is being updated to include the appropriate warnings and ...
Skip to main contentSkip to article
Adding Rituxan alongside standard therapies enhances the response patients have to treatment and improves overall outcomes, including increasing the time patients live for without experiencing a progression of their disease. Rituxan helps to improve overall survival in certain patients with CLL and also ...
a histologically confirmed diagnosis of mantle cell lymphoma or of indolent lymphoma, either refractory to or relapsed within 1 year after first-line polychemotherapy and requiring treatment; expression of CD20 by lymphoma cells; and availability of a molecular probe for PCR amplification of DNA to ...
Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study. Cladribine is approved to be used in 24-hour continuous infusion for the treatment of low-grade lymphoma by the Ministry of Health, Labor and Welfare in Ja... Y Takamatsu ...
(e.g. induction of cellular immunity; GVL predominance over GVHD; achievement of partial or complete responses; prolongation of time-to-progression) obtained from this phase I/II trial would represent the first milestone in the clinical evaluation of a novel immunotherapeutic concept for treatment-...
aUpdate Successful: pal4p.exe 更新成功: pal4p.exe [translate] a暗礁 Hidden rock [translate] asuite ROOM 随员室 [translate] a我对恶性血液病的细胞治疗很感兴趣,特别是NK细胞输注。 I am interested very much to the malignant nosohemia cell treatment, specially NK cell infusion. [translate] ...
Autologous chimeric antigen receptor (CAR) T cell therapies targeting CD19 have high efficacy in large B cell lymphomas (LBCLs), but long-term remissions are observed in less than half of patients, and treatment-associated adverse events, such as immune effector cell-associated neurotoxicity syndrom...
(CLL)recurrenceproducedaresponserateof54%aftera4-weektreatmentperiod.METHODS:Tooptimizedose,schedule,androuteofalemtu-zumab,astudywasdesignedexploringcontinuousintravenousinfusion(civ)followedbysubcutaneous(sc)alemtu-zumabtogetherwithweeklyivrituximabinpatientswithpreviouslytreatedCLL.RESULTS:Datafrom40patientswitha...
oberhelman, los angeles i was nervous about my at home ivig treatments at first and did not know what to expect. but divine infusion has made my ivig treatment comfortable and easy. my nurse is an angel–he is so kind and gentle and knowledgeable. i am so incredibly thankful for them!